Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy

B. A. Wilky, P. Kumthekar, R. Wesolowski, J. J. Hwang, S. I. Park, G. Yuan, C. D. Dupont, M. Lim, O. Shebanova, J. M. Cuillerot, E. Dow, W. Ortuzar, Jeffrey J Raizer, E. Drouin, N. Wilson, A. M. Gonzalez, J. M. Goldberg, J. S. Buell, R. B. Stein, H. Youssoufian

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)viii416-viii417
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this